Continuous or fractionated photodynamic therapy? Comparison of three PDT schemes for ovarian peritoneal micrometastasis treatment in a rat model

Photodiagnosis and Photodynamic Therapy

Volumn 7, Issue 4, 2010, Pages 251-257

  Estevez, Juan Pablo ^a,b   Ascencio, Manuel ^a,b   Colin, Pierre ^a   Farine, Marie Odile ^b   Collinet, Pierre ^a,b   Mordon, Serge ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Light fractionation; Ovarian cancer; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID HEXYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOMATOUS PERITONITIS; FEMALE; MICROMETASTASIS; NONHUMAN; OVARY CANCER; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RAT; TREATMENT PLANNING; TUMOR BIOPSY; TUMOR NECROSIS;

ADENOCARCINOMA; AMINOLEVULINIC ACID; ANIMALS; DISEASE MODELS, ANIMAL; FEMALE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RATS; RATS, INBRED F344;

RATTUS;

EID: 78649632215     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2010.07.007     Document Type: Article

References (46)

1. Benedet J.L., Bender H., Jones H., Ngan H.Y., Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000, 70(2):209-262.
2. Rensontet A., Velten M., Jougla E., Estève J. Evolution de l'incidence et de la mortalité par cancer en france de 1978 à 2000. Actis-Paris 2003, 119-124.
3. Eisenkop S.M., Nalick R.H., Wang H.J., Teng N.N. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993, 51(2):224-229.
4. McCarron P.A., Ma L.W., Juzenas P., et al. Facilitated delivery of ALA to inaccessible regions via bioadhesive patch systems. J Environ Pathol Toxicol Oncol 2006, 25(1-2):389-402.
5. Yamaguchi S., Tsuda H., Takemori M., et al. Photodynamic therapy for cervical intraepithelial neoplasia. Oncology 2005, 69(2):110-116.
6. Hillemanns P., Wang X., Staehle S., Michels W., Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol Oncol 2006, 100(2):271-275.
7. Jichlinski P. Photodynamic applications in superficial bladder cancer: facts and hopes. J Environ Pathol Toxicol Oncol 2006, 25(1-2):441-451.
8. Du K.L., Mick R., Busch T.M., et al. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med 2006, 38(5):427-434.
9. Witzigmann H., Berr F., Ringel U., et al. Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 2006, 244(2):230-239.
10. Mordon S., Maunoury V., Bulois P., et al. [Photodynamic therapy in gastroenterology]. Gastroenterol Clin Biol 2005, 29(8-9):949-954.
11. Pech O., Gossner L., May A., et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005, 62(1):24-30.
12. Gross S.A., Wolfsen H.C. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc Clin N Am 2010, 20(1):35-53.
13. Biel M. Advances in photodynamic therapy for the treatment of head and neck cancers. Lasers Surg Med 2006, 38(5):349-355.
14. Braathen L.R., Szeimies R.M., Basset-Seguin N., et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007, 56(1):125-143.
15. Torezan L., Niwa A.B., Neto C.F. Photodynamic therapy in dermatology: basic principles. An Bras Dermatol 2009, 84(5):445-459.
16. Lou P.J., Jager H.R., Jones L., et al. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004, 91(3):441-446.
17. Ascencio M., Estevez J.P., Delemer M., et al. Comparison of continuous and fractionated illumination during hexaminolaevulinate-photodynamic therapy. Photodiagnosis Photodyn Ther 2008, 5(3):210-216.
18. Kennedy J.C., Pottier R.H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992, 14(4):275-292.
19. Lopez R.F., Lange N., Guy R., Bentley M.V. Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Adv Drug Deliv Rev 2004, 56(1):77-94.
20. Wyld L., Burn J.L., Reed M.W., Brown N.J. Factors affecting aminolaevulinic acid-induced generation of protoporphyrin IX. Br J Cancer 1997, 76(6):705-712.
21. Leibovici L., Schoenfeld N., Yehoshua H.A., et al. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer 1988, 62(11):2297-2300.
22. el-Sharabasy M.M., el-Waseef A.M., Hafez M.M., Salim S.A. Porphyrin metabolism in some malignant diseases. Br J Cancer 1992, 65(3):409-412.
23. Brunner H., Hausmann F., Knuechel R. New 5-aminolevulinic acid esters-efficient protoporphyrin precursors for photodetection and photodynamic therapy. Photochem Photobiol 2003, 78(5):481-486.
24. El Khatib S., Didelon J., Leroux A., et al. Kinetics, biodistribution and therapeutic efficacy of hexylester 5-aminolevulinate induced photodynamic therapy in an orthotopic rat bladder tumor model. J Urol 2004, 172(5 Pt 1):2013-2017.
25. Lange N., Jichlinski P., Zellweger M., et al. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study. Br J Cancer 1999, 80(1-2):185-193.
26. Jouve E., Collinet P., Delemer-Lefebvre M., Mordon S. Alternative administrations of hexaminolevulinate (HeALA) for laparoscopic fluorescence diagnosis of metastatic ovarian cancer in a rat model. 15th Annual Congress of the European Society for Gynaecological endoscopy 2006, Medimond International Proceedings, Strasbourg.
27. Regis C., Collinet P., Farine M.O., Mordon S. Comparison of aminolevulinic acid- and hexylester aminolevulinate-induced protoporphyrin IX fluorescence for the detection of ovarian cancer in a rat model. Photomed Laser Surg 2007, 25(4):304-311.
28. Hua Z., Gibson S.L., Foster T.H., Hilf R. Effectiveness of delta-aminolevulinic acid-induced protoporphyrin as a photosensitizer for photodynamic therapy in vivo. Cancer Res 1995, 55(8):1723-1731.
29. Messmann H., Mlkvy P., Buonaccorsi G., et al. Enhancement of photodynamic therapy with 5-aminolaevulinic acid-induced porphyrin photosensitisation in normal rat colon by threshold and light fractionation studies. Br J Cancer 1995, 72(3):589-594.
30. Pogue B.W., Hasan T. A theoretical study of light fractionation and dose-rate effects in photodynamic therapy. Radiat Res 1997, 147(5):551-559.
31. Rose G.S., Tocco L.M., Granger G.A., et al. Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am J Obstet Gynecol 1996, 175(3 Pt 1):593-599.
32. Foster T.H., Murant R.S., Bryant R.G., et al. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res 1991, 126(3):296-303.
33. Ascencio M., Delemer M., Farine M.O., et al. Evaluation of ALA-PDT of ovarian cancer in the Fischer 344 rat tumor model. Photodiagn Photodyn Ther 2007, 4(4):254-260.
34. Mlkvy P., Messmann H., Pauer M., et al. Distribution and photodynamic effects of meso-tetrahydroxyphenylchlorin (mTHPC) in the pancreas and adjacent tissues in the Syrian golden hamster. Br J Cancer 1996, 73(12):1473-1479.
35. Muller S., Walt H., Dobler-Girdziunaite D., Fiedler D., Haller U. Enhanced photodynamic effects using fractionated laser light. J Photochem Photobiol B 1998, 42(1):67-70.
36. Pe M.B., Ikeda H., Inokuchi T. Tumor destruction and proliferation kinetics following periodic, low power light, haematoporphyrin oligomers mediated photodynamic therapy in the mouse tongue. Eur J Cancer B Oral Oncol 1994, 30B(3):174-178.
37. Curnow A., Haller J.C., Bown S.G. Oxygen monitoring during 5-aminolaevulinic acid induced photodynamic therapy in normal rat colon. Comparison of continuous and fractionated light regimes. J Photochem Photobiol B 2000, 58(2-3):149-155.
38. Curnow A., Bown S.G. The role of reperfusion injury in photodynamic therapy with 5-aminolaevulinic acid-a study on normal rat colon. Br J Cancer 2002, 86(6):989-992.
39. Dietel W., Pottier R., Pfister W., Schleier P., Zinner K. 5-Aminolaevulinic acid (ALA) induced formation of different fluorescent porphyrins: a study of the biosynthesis of porphyrins by bacteria of the human digestive tract. J Photochem Photobiol B 1997, 86(1):77-86.
40. Curnow A., McIlroy B.W., Postle-Hacon M.J., MacRobert A.J., Bown S.G. Light dose fractionation to enhance photodynamic therapy using 5-aminolevulinic acid in the normal rat colon. Photochem Photobiol 1999, 69(1):71-76.
41. Iinuma S., Schomacker K.T., Wagnieres G., et al. In vivo fluence rate and fractionation effects on tumor response and photobleaching: photodynamic therapy with two photosensitizers in an orthotopic rat tumor model. Cancer Res 1999, 59(24):6164-6170.
42. de Bruijn H.S., van der Ploeg-van den Heuvel A., Sterenborg H.J., Robinson D.J. Fractionated illumination after topical application of 5-aminolevulinic acid on normal skin of hairless mice: the influence of the dark interval. J Photochem Photobiol B 2006, 85(3):184-190.
43. Curnow A., MacRobert A.J., Bown S.G. Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid. Lasers Surg Med 2006, 38(4):325-331.
44. Foster T.H., Hartley D.F., Nichols M.G., Hilf R. Fluence rate effects in photodynamic therapy of multicell tumor spheroids. Cancer Res 1993, 53(6):1249-1254.
45. Veenhuizen R.B., Stewart F.A. The importance of fluence rate in photodynamic therapy: is there a parallel with ionizing radiation dose-rate effects?. Radiother Oncol 1995, 37(2):131-135.
46. Henderson B.W., Busch T.M., Snyder J.W. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 2006, 38(5):489-493.